A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 80 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 5th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
This study's enrollment of 210 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 in phase 3, and was the 14th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma.
Secondary Objectives:
The total study duration per participant was up to 46 weeks, consisting of a screening period of 3 to up to 8 weeks (up to 10 weeks for participants who experienced a clinically significant asthma exacerbation during the screening period), a randomized treatment period of up to 24 weeks, and a post-treatment period of 12 weeks.
Participants who completed treatment were considered for eligibility into the long term extension study LTS12551 (NCT02134028).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult and adolescent (12 years of age or older) participants with a physician diagnosis of asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2014 guidelines and the following criteria:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Placebo · Drug: Oral corticosteroid therapy (prednisone/prednisolone) · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Dupilumab · Drug: Oral corticosteroid therapy (prednisone/prednisolone) · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Also known as: REGN668, SAR231893
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Oral administration.
Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
Drug page: Albuterol
Oral inhalation as needed.
Drug page: Levalbuterol
Oral inhalation as needed.
Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control
Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.
Time frame: Baseline, Week 24
Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.
Time frame: Baseline, Week 24
Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.
Time frame: Week 24
Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control
Participants were classified according to the binary status of whether or not the reduction of OCS dose to \<5 mg/day was achieved at Week 24.
Time frame: Week 24
Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control
For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).
Time frame: Week 24
Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.
Time frame: Week 24
Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
Absolute reduction was calculated by subtracting Week 24 value from baseline value.
Time frame: Baseline and Week 24
Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period
A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 24
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24
The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24
AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24
EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24
The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24
The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
Time frame: Baseline, Week 12 and Week 24
The study was conducted at 68 centers in 17 countries. A total of 390 participants were screened between October 2015 \& April 2017, of which,210 were randomized \& treated. 180 participants were screen failures mainly due to exclusion criteria met \& inclusion criteria not met. Assignment was done by Interactive Voice/Web Response System(IVRS/IWRS).
| Milestone | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Started | 107 | 103 |
| Treated | 107 | 103 |
| Completed | 107 | 100 |
| Not completed | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Other than specified above | 0 | 1 |
Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.
| Percentage reduction from baseline | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control | 41.85 ± 4.57 | 70.09 ± 4.90 |
The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.
| percentage reduction from baseline | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control | 50.0 (0 to 100.0) | 100.0 (62.5 to 100.0) |
Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.
| percentage of participants | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control | 53.3 | 79.6 |
Participants were classified according to the binary status of whether or not the reduction of OCS dose to \<5 mg/day was achieved at Week 24.
| percentage of participants | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control | 37.4 | 71.8 |
For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).
| percentage of participants | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control | 29.9 | 52.4 |
Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.
| percentage of participants | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control | 29.2 | 52.4 |
Absolute reduction was calculated by subtracting Week 24 value from baseline value.
| mg/day | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Baseline | 11.75 ± 6.31 | 10.75 ± 5.90 |
| Week 24 | 6.32 ± 6.75 | 3.13 ± 5.44 |
| Absolute reduction at Week 24 | 5.45 ± 6.80 | 7.66 ± 6.10 |
A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period | 1.597 (1.248 to 2.043) | 0.649 (0.442 to 0.955) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Baseline | 1.63 ± 0.61 | 1.53 ± 0.53 |
| Week 12 | 1.68 ± 0.61 | 1.82 ± 0.63 |
| Change at Week 12 | 0.06 ± 0.50 | 0.29 ± 0.43 |
| Week 24 | 1.63 ± 0.65 | 1.84 ± 0.60 |
| Change at Week 24 | 0.00 ± 0.51 | 0.29 ± 0.46 |
The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| score on a scale | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Change at Week 2 | -0.18 ± 0.67 | -0.49 ± 0.86 |
| Change at Week 4 | -0.36 ± 0.81 | -0.61 ± 1.01 |
| Change at Week 8 | -0.39 ± 1.13 | -0.68 ± 1.06 |
| Change at Week 12 | -0.54 ± 1.17 | -0.92 ± 1.09 |
| Change at Week 16 | -0.57 ± 1.05 | -0.87 ± 1.18 |
| Change at Week 20 | -0.53 ± 1.09 | -0.83 ± 1.19 |
| Change at Week 24 | -0.57 ± 1.19 | -0.94 ± 1.22 |
AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| score on a scale | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Change at Week 12 | 0.56 ± 1.08 | 0.78 ± 1.09 |
| Change at Week 24 | 0.56 ± 0.97 | 0.94 ± 1.17 |
EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
| score on a scale | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Single Index: Change at Week 12 | 0.04 ± 0.20 | 0.03 ± 0.17 |
| Single Index: Change at Week 24 | 0.05 ± 0.18 | 0.05 ± 0.18 |
| VAS Score: Change at Week 12 | 5.99 ± 16.85 | 9.34 ± 18.20 |
| VAS Score: Change at Week 24 | 4.16 ± 16.74 | 11.06 ± 17.60 |
The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
| score on a scale | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Change at Week 12 | -0.75 ± 5.50 | -2.13 ± 5.32 |
| Change at Week 24 | -0.99 ± 5.36 | -2.53 ± 5.98 |
The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
| score on a scale | Placebo q2w | Dupilumab 300 mg q2w |
|---|---|---|
| Change at Week 12 | -3.79 ± 21.34 | -12.45 ± 17.10 |
| Change at Week 24 | -2.46 ± 19.11 | -14.56 ± 15.89 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo q2w | 0/107 (0%) | 6/107 (5.6%) | 30/107 (28%) |
| Dupilumab 300mg q2w | 0/103 (0%) | 9/103 (8.7%) | 29/103 (28.2%) |
| Event | Placebo q2w | Dupilumab 300mg q2w |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/107 | 3/103 |
| EosinophiliaBlood and lymphatic system disorders | 0/107 | 2/103 |
| PneumoniaInfections and infestations | 0/107 | 1/103 |
| Respiratory tract infectionInfections and infestations | 0/107 | 1/103 |
| ChylothoraxRespiratory, thoracic and mediastinal disorders | 0/107 | 1/103 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/107 | 1/103 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/107 | 1/103 |
| Pulmonary massRespiratory, thoracic and mediastinal disorders | 0/107 | 1/103 |
| Acetabulum fractureInjury, poisoning and procedural complications | 0/107 | 1/103 |
| Foreign body aspirationInjury, poisoning and procedural complications | 0/107 | 1/103 |
| Event | Placebo q2w | Dupilumab 300mg q2w |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 19/107 | 9/103 |
| BronchitisInfections and infestations | 6/107 | 7/103 |
| SinusitisInfections and infestations | 4/107 | 7/103 |
| Eosinophil count increasedInvestigations | 0/107 | 7/103 |
| InfluenzaInfections and infestations | 6/107 | 3/103 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Mean | 50.7 ± 12.8 | 51.9 ± 12.5 | 51.3 ± 12.6 |
| Age, Customized(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| <18 years | 2 | 1 | 3 |
| Between 18 and 64 years | 88 | 91 | 179 |
| >=65 years | 17 | 11 | 28 |
| Sex: Female, Male(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Female | 65 | 62 | 127 |
| Male | 42 | 41 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 23 | 45 |
| Not Hispanic or Latino | 85 | 80 | 165 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Caucasian/White | 100 | 97 | 197 |
| Black/of African descent | 1 | 4 | 5 |
| Asian/Oriental | 2 | 0 | 2 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 2 | 1 | 3 |
| Baseline Blood Eosinophil Count(Participants) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| <0.15 Giga/L | 38 | 22 | 60 |
| >=0.15 - <0.3 Giga/L | 28 | 33 | 61 |
| >=0.3 Giga/L | 41 | 48 | 89 |
| Baseline Optimized Daily OCS Dose(mg/day) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Mean | 11.75 ± 6.31 | 10.75 ± 5.9 | 11.26 ± 6.12 |
| Daily OCS Dose at Visit 1 (i.e. preoptimization)(mg/day) | Placebo q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|
| Mean | 11.83 ± 6.02 | 11.79 ± 6.4 | 11.81 ± 6.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2015, a primary completion of Sep 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab